NASDAQ:REGN - Regeneron Pharmaceuticals Stock Price, Price Target & More

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced its earnings results on Thursday, May, 3rd. The biopharmaceutical company reported $4.67 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $5.08 by $0.41. The biopharmaceutical company had revenue of $1.51 billion for the quarter, compared to the consensus estimate of $1.50 billion. Regeneron Pharmaceuticals had a return on equity of 29.92% and a net margin of 23.54%. The firm's revenue for the quarter was up 14.6% compared to the same quarter last year. During the same period in the prior year, the business posted $2.92 earnings per share. View Regeneron Pharmaceuticals' Earnings History.

Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Regeneron Pharmaceuticals.

24 brokers have issued 12 month price objectives for Regeneron Pharmaceuticals' stock. Their forecasts range from $290.00 to $593.00. On average, they anticipate Regeneron Pharmaceuticals' stock price to reach $421.1667 in the next year. This suggests a possible upside of 14.5% from the stock's current price. View Analyst Ratings for Regeneron Pharmaceuticals.

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 13 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Regeneron Pharmaceuticals include AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS) and Takeda Pharmaceutical (TKPYY).

Headlines about REGN stock have trended positive this week, Accern reports. The research firm ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Regeneron Pharmaceuticals earned a news sentiment score of 0.26 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 46.64 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Regeneron Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include SANOFI (95.60%), Manning & Napier Group LLC (0.48%), Assenagon Asset Management S.A. (0.11%), ADAMCAPITAL Gestao de Recursos Ltda. (0.10%), Bank of Montreal Can (0.04%) and Retirement Systems of Alabama (0.03%). Company insiders that own Regeneron Pharmaceuticals stock include Arthur F Ryan, Charles A Baker, George L Sing, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry, Robert J Terifay and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.

REGN stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, ADAMCAPITAL Gestao de Recursos Ltda., Westpac Banking Corp, Huntington National Bank, Nisa Investment Advisors LLC, Prentiss Smith & Co. Inc., Boston Advisors LLC and Hartford Investment Management Co.. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Charles A Baker, George L Sing, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Sanofi. View Insider Buying and Selling for Regeneron Pharmaceuticals.

REGN stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Manning & Napier Group LLC, Financial & Investment Management Group Ltd., Essex Investment Management Co. LLC, State of Alaska Department of Revenue, IFM Investors Pty Ltd, CWM Advisors LLC and Fred Alger Management Inc.. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of REGN stock can currently be purchased for approximately $367.74.

Regeneron Pharmaceuticals has a market capitalization of $39.36 billion and generates $5.87 billion in revenue each year. The biopharmaceutical company earns $1.20 billion in net income (profit) each year or $13.41 on an earnings per share basis. Regeneron Pharmaceuticals employs 6,200 workers across the globe.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]